QUOTED. 22 September 2020. Francis deSouza.
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
“Galleri is among the most promising new tools in the fight against cancer, and we are thrilled to welcome Grail back to Illumina to help transform cancer care using genomics and our next-generation sequencing platform.” – Francis deSouza, CEO, Illumina
Click here for a free trial of Medtech Insight